Last reviewed · How we verify
Acetaminophen IV/PO
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system.
Acetaminophen reduces pain and fever by inhibiting prostaglandin synthesis in the central nervous system. Used for Fever reduction, Mild to moderate pain relief.
At a glance
| Generic name | Acetaminophen IV/PO |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Analgesic and antipyretic |
| Target | Cyclooxygenase (COX) enzymes; possibly TRPV1 and other pain pathways |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Acetaminophen is believed to work primarily through inhibition of cyclooxygenase (COX) enzymes in the brain and spinal cord, reducing prostaglandin production and thereby lowering the pain threshold and resetting the hypothalamic thermostat. The exact mechanism remains incompletely understood, but it does not significantly inhibit peripheral COX enzymes like NSAIDs do. Both intravenous and oral formulations deliver the same active compound with similar mechanisms of action, though IV administration provides faster onset.
Approved indications
- Mild to moderate pain
- Fever reduction
Common side effects
- Hepatotoxicity (at high doses or chronic use)
- Nausea
- Rash
- Hypersensitivity reactions
Key clinical trials
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters (PHASE2)
- A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (PHASE2)
- Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304) (PHASE2)
- Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma (PHASE2)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (PHASE3)
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acetaminophen IV/PO CI brief — competitive landscape report
- Acetaminophen IV/PO updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI